COMMD7 activates CXCL10 production by regulating NF-κB and the production of reactive oxygen species

  • Authors:
    • Nan You
    • Jing Li
    • Xiaobing Huang
    • Ke Wu
    • Yichen Tang
    • Liang Wang
    • Hongyan Li
    • Na Mi
    • Lu Zheng
  • View Affiliations

  • Published online on: March 8, 2018     https://doi.org/10.3892/mmr.2018.8706
  • Pages: 6784-6788
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

While >80% of the incidence occurs in sub‑Saharan Africa and East Asia, cases of hepatocellular carcinoma (HCC) have been rapidly increasing in Western countries. Despite its global importance, HCC is relatively under‑researched compared with other lethal cancer types, which is possibly due to the high complexity and heterogeneity of HCC. It has been reported previously that COMM domain‑containing protein 7 (COMMD7) is upregulated in HCC and promotes HCC cell proliferation by triggering C‑X‑C motif chemokine 10 (CXCL10) production. However, the value of targeting CXCL10 signal transduction in treating COMMD7‑positive tumors, or the molecular mechanisms underlying COMMD7‑mediated CXCL10 expression, has not been completely addressed. In the present study, it was demonstrated that disruption of the CXCL10/C‑X‑C chemokine receptor type 3 axis reduces COMMD7‑mediated HCC cell proliferation. Furthermore, COMMD7 modulates CXCL10 production by activating nuclear factor (NF)‑κB. Additionally, it was demonstrated that intracellular reactive oxygen species (ROS) are required for NF‑κB activation and CXCL10 production. In conclusion, COMMD7 activates CXCL10 production by regulating NF‑κB and the production of ROS. The present study highlighted the role of COMMD7 in the development of HCC, and provides novel options for anticancer drug design.

References

1 

El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI

2 

Bruix J, Gores GJ and Mazzaferro V: Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Arzumanyan A, Reis HM and Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M and Falck-Ytter Y: Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies. Ann Intern Med. 158:329–337. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Zheng L, Liang P, Li J, Huang XB, Liu SC, Zhao HZ, Han KQ and Wang Z: ShRNA-targeted COMMD7 suppresses hepatocellular carcinoma growth. PLoS One. 7:e454122012. View Article : Google Scholar : PubMed/NCBI

6 

van Wanrooij EJ, de Jager SC, van Es T, de Vos P, Birch HL, Owen DA, Watson RJ, Biessen EA, Chapman GA, van Berkel TJ and Kuiper J: CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 28:251–257. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Ni H, Zhao W, Kong X, Li H and Ouyang J: NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis. PLoS One. 9:e958462014. View Article : Google Scholar : PubMed/NCBI

8 

Matteucci C, Minutolo A, Marino-Merlo F, Grelli S, Frezza C, Mastino A and Macchi B: Characterization of the enhanced apoptotic response to azidothymidine by pharmacological inhibition of NF-kB. Life Sci. 127:90–97. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Gilmore TD: Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P, Nürnberg P, Mann NP, Banerjee R, Saka HN, et al: Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet. 44:740–742. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Chang JH, Kim YJ, Han SH and Kang CY: IFN-gamma-STAT1 signal regulates the differentiation of inducible Treg: Potential role for ROS-mediated apoptosis. Eur J Immunol. 39:1241–1251. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer. 6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI

14 

Lazennec G and Richmond A: Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol Med. 16:133–144. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM and Pal S: Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: Relevance for the development of human breast cancer. Cancer Res. 66:9509–9518. 2006. View Article : Google Scholar : PubMed/NCBI

16 

Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, Sakai Y, Takabayashi A, Oshima M and Taketo MM: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene. 26:4679–4688. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Ding Q, Xia Y, Ding S, Lu P, Sun L and Liu M: An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9. Oncotarget. 7:14405–14414. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Ling CC, Ng KT, Shao Y, Geng W, Xiao JW, Liu H, Li CX, Liu XB, Ma YY, Yeung WH, et al: Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth. J Hepatol. 60:103–109. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Zhu Y, Wang Z, Zhu Y, Wang J, Cai L, Shen H, Kong Y and Qiu Y: CXCR3 monoclonal antibody inhibits the proliferation and migration of MCF-7 cells and HepG2 cells in vitro. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 31:1544–1548. 2015.(In Chinese). PubMed/NCBI

20 

Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR and Beard MR: Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology. 39:1220–1229. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Guo JQ, Chen L, Ai HW, Jing JN, Zhou JY, Zhang CY and You SY: A novel fusion protein of IP10-scFv retains antibody specificity and chemokine function. Biochem Biophys Res Commun. 320:506–513. 2004. View Article : Google Scholar : PubMed/NCBI

22 

Huang YT, Chen YY, Lai YH, Cheng CC, Lin TC, Su YS, Liu CH and Lai PC: Resveratrol alleviates the cytotoxicity induced by the radiocontrast agent, ioxitalamate, by reducing the production of reactive oxygen species in HK-2 human renal proximal tubule epithelial cells in vitro. Int J Mol Med. 37:83–91. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Karthik S, Sankar R, Varunkumar K, Anusha C and Ravikumar V: Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species. Biomed Pharmacother. 69:337–344. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May 2018
Volume 17 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
You, N., Li, J., Huang, X., Wu, K., Tang, Y., Wang, L. ... Zheng, L. (2018). COMMD7 activates CXCL10 production by regulating NF-κB and the production of reactive oxygen species. Molecular Medicine Reports, 17, 6784-6788. https://doi.org/10.3892/mmr.2018.8706
MLA
You, N., Li, J., Huang, X., Wu, K., Tang, Y., Wang, L., Li, H., Mi, N., Zheng, L."COMMD7 activates CXCL10 production by regulating NF-κB and the production of reactive oxygen species". Molecular Medicine Reports 17.5 (2018): 6784-6788.
Chicago
You, N., Li, J., Huang, X., Wu, K., Tang, Y., Wang, L., Li, H., Mi, N., Zheng, L."COMMD7 activates CXCL10 production by regulating NF-κB and the production of reactive oxygen species". Molecular Medicine Reports 17, no. 5 (2018): 6784-6788. https://doi.org/10.3892/mmr.2018.8706